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The verb “salvage”, according to Oxford Dictionary, is to save property 
from shipwreck, ﬁre or war, implying maximization of beneﬁt in a 
relatively hopeless situation. “Salvage therapy” carries a similar mean-
ing of being a therapy with remote hope of beneﬁt. Patient should be 
in a medical condition that is beyond cure or survival prolongation and 
therapy may only help in a small portion of patients. Stage IIIB and IV 
non-small-cell lung cancer (NSCLC) is not a curable condition at diag-
nosis, however, ﬁrst line systemic chemotherapy offers a good chance 
of survival prolongation and improvement of quality of life.(1-2) Plati-
num-based doublet with a third generation cytotoxic drug such as gem-
citabine, paclitaxel, vinorelbine or docetaxel is an universally accepted 
standard therapy. Upon treatment failure to ﬁrst line therapy a number 
of approved second line therapies including docetaxel, pemetrexed, 
erlotinib and geﬁtinib are now available. Single agent docetaxel at 
75mg/m2 every 3 weeks can attain tumor response rate of less than 10% 
but the median survival of 7.5 months which was statistically higher 
than the 4.6 months in the best supportive care group.(3) Pemetrexed 
was approved in 2004 when Hanna et al demonstrated in a randomized 
study showing that the medians survival of pemetrexed to be similar to 
docetaxel as second line therapy (8.3 months and 7.9 months, respec-
tively).(4) Therefore second line chemotherapy is now considered to be 
standard treatment rather than “salvage therapy”. Erlotinib is an epider-
mal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that 
was shown in a randomized comparative study to attain survival beneﬁt 
for patients who failed one or more line of chemotherapy. This pivotal 
study (BR-21) reported median survival of 6.7 months versus 4.7 
months in erlotinib and placebo group respectively.(5) Geﬁtnib shares 
similar mechanism of action but its survival outcomes in a randomized 
phase III study (ISEL)failed to reach signiﬁcant statistic endpoint.(6) In 
the subgroup analysis ISEL survival beneﬁt was reported in non-smok-
er, adenocarcinoma and patients of Asian decent. 
For the beneﬁt of this session, we deﬁne salvage therapy as treatment 
from 3rd line onward or therapy for situation with no established 
survival beneﬁt. This would include salvage therapy for failure to sec-
ond-line chemotherapy, salvage therapy for EFGR-TKI resistance and 
salvage therapy for brain metastasis after failing whole brain radiother-
apy (WBRT). We shall examine some of the early data and try to judge 
if their potential toxicity is worthy of their limited efﬁcacy. 
Salvage therapy for failure to second-line chemotherapy 
Massarelli et al (7) examined the outcomes of third/fourth line therapy 
in a retrospective study. They reviewed 700 patient records and identi-
ﬁed 43 patients who had received third/fourth line therapy after failing 
platinum-based doublet and docetaxel. Tumor response rate declined 
with each line of chemotherapy: ﬁrst line, 20.9%; second line 16.3
%; third line, 2.3%; and fourth line, 0%. Median overall survival was 
16.4 months from the date of diagnosis but only 4 months from third/
fourth line chemotherapy. The ﬁnding suggested that chemotherapy 
beyond second line has limited efﬁcacy. However, this study is limited 
by selecting patients who has failed with disease progression or toxicity 
within 90 days of prior treatment. We cannot deny that patients with a 
durable response to ﬁrst line chemotherapy may have potential beneﬁt 
from re-challenge with chemotherapy. Clinical trial on this subgroup of 
patient is lacking. Thus a better approach to patients who failed 2 line 
of chemotherapy is biologic therapy such as erlotinib or geﬁtinib.(5-6) 
It is known that somatic mutation at EGFR explains the dramatic clini-
cal responsiveness to EGFR-TKI.(8,9) Shigematsu et al (10) identiﬁed 
a signiﬁcant difference in incidence between gender (female 42% vs 
male 14%, p<0.01), ethnicity (Asian 30% vs non-Asian 8%), smok-
ing status (never smoker 51% versus 10% ex- or ongoing smoker) and 
histology (adencocarinocma 40% vs other histology <3%). In Asia the 
histologic subtype of adenocarcinoma was found to be the strongest 
predictor of EGFR mutation.(11) Therefore the salvage therapy for pa-
tients with adenocarcinoma after failing 2 lines of chemotherapy should 
be EGFR TKI. 
The role of anti-angiogenesis in combination with chemotherapy in 
third/fourth line has not been well deﬁned. Two randomized stud-
ies have shown that the combination of bevacizumab (a monoclonal 
antibody against the ligand of circulating VEGF) and doublet chemo-
therapy has additional beneﬁt over standard ﬁrst line platinum-based 
combination.(12) Use of single agent bevacizumab in second/third line 
has limited efﬁcacy. Addition of bevacizumab to second line single 
agent chemotherapy was studied in a randomized phase II study (13) 
that reported a trend towards improvement with the combination. A 
phase III study is ongoing.
Salvage therapy for EGFR TKI resistance
EGFR activation triggers downstream signaling that sustains cell 
survival and proliferation. TKI of the EGFR targets the ATP-binding 
domain and results in suppression of tumor growth. Most patients who 
Journal of Thoracic Oncology • Volume 2, Number 8, Supplement 4, August 2007  12th World Conference on Lung Cancer
Copyright © 2007 by the International Association for the Study of Lung CancerS290
attain partial response would have a sustainable tumor control but the 
overall progression-free survival was limited in BR-21 and ISEL. Only 
for speciﬁc patients with known EGFR mutation their median progres-
sion free survival could be over 13.5 months.(14) However, almost all 
patients will eventually fails.
Acquired resistance to EGFR TKI occurs in patients with EGFR TKI 
failure. The T790M mutation at exon 20 is known to abrogate the TKI’s 
ability by binding to the EGFR kinase domain.(15) Engelman et al was 
able to demonstrate in an in vitro model that prolonged exposure of 
geﬁtinib to sensitive cell line may result in acquired T790M mutation. 
Introduction of T790M mutation would confer resistance to geﬁtinib and 
reinstall the signaling of PI3K/Akt pathway.(16) Prevalence of T790M 
was believed to account for 50% of EGFR TKI resistance but the ac-
curacy was limited by the small sample size. Other possible mechanism 
has also been proposed. The same group found over-expression of 
cMET in 22% of patients with EGFR TKI resistance.(17) Other muta-
tions along the PI3k or Ras pathway may also contribute to acquired 
resistance of EGFR TKI but this remains relatively less well deﬁned.
A number of methods have been proposed to overcome resistance to 
EGFR TKI. Monoclonal antibody against EGFR such as Cetuximab 
or panitumab inhibits the extra-celluar domain of the EGFR while the 
EGFR TKI inhibits the intra-cellular domain. Mok et al (18) attempt to 
overcome geﬁtinib resistance by combined targeting of geﬁtinib with 
monoclonal antibodies cetuximab and/or trastuzumab. The hypothesis 
was that combination of monoclonal antibodies with geﬁtinib may elicit 
synergistic antitumor activity in geﬁtinib-resistant NSCLC cell line. 
Percentage of cell kill by combined treatment of cetuximab and geﬁtinib 
on NCI-H1975 (geﬁtinib-resistant) was superior to geﬁtinib alone, and 
the combination was able to restore to level similar to geﬁtnib alone on 
the sensitive cell line (NCI-H1975). The geﬁtinib/cetuximab combina-
tion, but not geﬁtinib alone, was able to down-regulate EGF-induced 
phosphorylation of Akt and MAPK in NCI-H1975 in a dose-dependent 
manner. To date there is no clinical study on the combination. 
Zactima (ZD 6474) is a dual inhibitor of EGFR and VEGFR. Random-
ized phase II studies suggested it to be an active second line agent for 
patients who fails chemotherapy. A randomized phase III study that 
compares Zactima with supportive care in patients who fails EGFR 
TKI is ongoing. Other investigational biologic drugs with multi-kinase 
inhibition may also share the potential. Sorentinib was tested in a single 
agent trial in patients with relapsed NSCLC. Preliminary data sug-
gested tumor response rate approaching 10%.(19) There is no collective 
data of sorentinib in patients with EGFR TKI failure.
Salvage for brain metastasis after failing WBRT
WBRT is the standard therapy for brain metastasis which is associated 
with limited duration of disease control. Upon disease progression 
there is no standard therapy. If tumor progression is conﬁned to solitary 
lesion, Cyberknife may be able to deliver concise radiation to the tumor 
site. Cyberknife is an image guided “frameless” radiosurgery that 
hold promises to provide “second line” treatment to progressive brain 
metastasis after failure WBRT.(20) Use of systemic therapy is also 
feasible. Robinet et al (21) reported tumor response rate of 20% as ﬁrst 
line therapy for patients with brain metastasis. Limited data is avail-
able in patients with WBRT failure. EGFR TKI is an attractive option. 
Two single arm phase II study reported response rate of 10% and 37% 
in a western and Asian population, respectively. Patients with clinical 
parameters that predict EGFR mutation are more likely to beneﬁt from 
EGFR TKI. 
Summary
Salvage therapy are treatment without established survival beneﬁt. 
However, ongoing research would suggest that a selective group of 
patients may beneﬁt from such treatment. The approach to salvage 
therapy should be rational and counterbalanced with patient’s general 
performance status and potential toxicity.
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